Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome

“…The M. D. Anderson Cancer Center compared the survival of 48 patients with limited-stage NLPHL by treatment received (CMT alone n ϭ 11 vs radiotherapy alone n ϭ 37) and found no difference in outcome (10-year relapse-free survival 77% vs 68%, P ϭ .89); however, patient numbers were small and the chemotherapy used may be inferior to ABVD (MOPP or NOVP (mitoxantrone, vincristine, vinblastine, and prednisone). 16 Feugier et al reported a 10-year FFP (failure from progression) of 80% using combined modality therapy in 42 patients with stage IA (n ϭ 24) or 2A (n ϭ 18) disease, but treatment was variable in some cases using only 1 cycle of ABVD or alternate chemotherapy EBVM, which also may not have similar efficacy to ABVD 14 (Table 2). A recently published population-based study with pathologic review evaluated 113 patients, with "early"-stage NLPHL, including 93 patients treated with radiotherapy alone and 20 who had received either CMT (n ϭ 13) or chemotherapy For personal use only.…”

Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

“…36,40,41 The ETFL project showed 96% complete remission for NLPHL, somewhat higher than for the cHL cases (nodular sclerosis, 89%; mixed cellularity, 93%). The HL specific survival and failure-free survival of NLPHL cases at 8 years were 95% and 74%, respectively, with an OS of 89%.…”

“…The study suggests that NLPHL and cHL patients without MI have a similar prognosis after a brief anthracycline-based chemotherapy regimen followed by extended field radiation. 41 The more recent comprehensive GHSG analysis evaluated clinical trail results of 8298 HL patients, of whom 394 were NLPHL and 7904 cHL. CR/CRu was reached in 91% of NLPHL patients vs. 86% cHL patients in early stages, 86% vs 83% in early unfavorable, and 79% vs 75% in advanced stages.…”

T-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management

“…NLPHL presents at a limited stage in the majority of cases, shows a male predominance, and follows a remarkably indolent natural history [20]. Most cases involve nodal sites while sparing the mediastinum [34]. This entity may be mistaken histologically for T/HRBCL (Fig.…”